Phoenix Biotech Acquisition Valuation
| PBAXUDelisted Stock | USD 10.87 0.00 0.00% |
At this time, the company appears to be overvalued. Phoenix Biotech Acqu holds a recent Real Value of $9.28 per share. The prevailing price of the company is $10.87. Our model determines the value of Phoenix Biotech Acqu from analyzing the company fundamentals such as Return On Asset of -0.0255, net income of (2.52 M), and Cash Per Share of 0.02 X as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Phoenix Biotech's price fluctuation is very steady at this time. Calculation of the real value of Phoenix Biotech Acqu is based on 3 months time horizon. Increasing Phoenix Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Phoenix Biotech's intrinsic value may or may not be the same as its current market price of 10.87, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.87 | Real 9.28 | Hype 10.87 | Naive 10.63 |
The intrinsic value of Phoenix Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Phoenix Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Phoenix Biotech Acquisition helps investors to forecast how Phoenix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Phoenix Biotech more accurately as focusing exclusively on Phoenix Biotech's fundamentals will not take into account other important factors: Phoenix Biotech Total Value Analysis
Phoenix Biotech Acquisition is at this time anticipated to have takeover price of 66.05 M with market capitalization of 66.05 M, debt of 650 K, and cash on hands of 553.77 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Phoenix Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
66.05 M | 66.05 M | 650 K | 553.77 K |
Phoenix Biotech Asset Utilization
One of the ways to look at asset utilization of Phoenix is to check how much profit was generated for every dollar of assets it reports. Phoenix Biotech holds a negative application of assets of -0.0255 pct., losing $2.55E-4 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Phoenix Biotech Acquisition shows how discouraging it operates for each dollar spent on its assets.Phoenix Biotech Profitability Analysis
Net Loss for the year was (2.52 M) with profit before overhead, payroll, taxes, and interest of 0.About Phoenix Biotech Valuation
The delisted stock valuation mechanism determines Phoenix Biotech's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Phoenix Biotech Acqu based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Phoenix Biotech. We calculate exposure to Phoenix Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Phoenix Biotech's related companies.Phoenix Biotech Acquisition Corp. does not have significant operations. The company was incorporated in 2021 and is based in Oakland, California. Phoenix Biotech is traded on NASDAQ Exchange in the United States.
Phoenix Biotech Growth Indicators
Investing in growth stocks can be very risky. If the company such as Phoenix Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 17.9 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Phoenix Stock
If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |